U.S. flag

An official website of the United States government

NM_000251.3(MSH2):c.1864C>A (p.Pro622Thr) AND not provided

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
Mar 6, 2017
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000255200.1

Allele description [Variation Report for NM_000251.3(MSH2):c.1864C>A (p.Pro622Thr)]

NM_000251.3(MSH2):c.1864C>A (p.Pro622Thr)

Gene:
MSH2:mutS homolog 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
2p21
Genomic location:
Preferred name:
NM_000251.3(MSH2):c.1864C>A (p.Pro622Thr)
HGVS:
  • NC_000002.12:g.47475129C>A
  • NG_007110.2:g.77006C>A
  • NM_000251.3:c.1864C>AMANE SELECT
  • NM_001258281.1:c.1666C>A
  • NP_000242.1:p.Pro622Thr
  • NP_000242.1:p.Pro622Thr
  • NP_001245210.1:p.Pro556Thr
  • LRG_218t1:c.1864C>A
  • LRG_218:g.77006C>A
  • LRG_218p1:p.Pro622Thr
  • NC_000002.11:g.47702268C>A
  • NM_000251.1:c.1864C>A
  • NM_000251.2:c.1864C>A
Protein change:
P556T
Links:
dbSNP: rs63750280
NCBI 1000 Genomes Browser:
rs63750280
Molecular consequence:
  • NM_000251.3:c.1864C>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001258281.1:c.1666C>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000322358GeneDx
criteria provided, single submitter

(GeneDx Variant Classification (06012015))
Likely pathogenic
(Mar 6, 2017)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From GeneDx, SCV000322358.7

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

This variant is denoted MSH2 c.1864C>A at the cDNA level, p.Pro622Thr (P622T) at the protein level, and results in the change of a Proline to a Threonine (CCA>ACA). This variant was observed in at least one individual from with colorectal cancer as well as MSH2-absent bladder and ureter cancers (Skeldon 2013). This variant was also identified in an individual with colon cancer from a family meeting Amsterdam I criteria (Chialina 2006). In addition, a different variant at the same position, Pro622Leu, has been reported in individuals with Lynch syndrome and functional studies have demonstrated impaired function compared to wild type (Mastrocola 2010, Drost 2012, Thompson 2013).MSH2 Pro622Thr was not observed in large population cohorts (Lek 2016, The 1000 Genomes Consortium 2015, NHLBI Exome Sequencing Project). Since Proline and Threonine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. MSH2 Pro622Thr occurs at a position that is conserved across species and is located in the ATPase domain and the region of interaction with EXO1 (Lutzen 2008). In silico analyses predict that this variant is probably damaging to protein structure and function. Based on the currently available evidence, we consider MSH2 Pro622Thr to be a likely pathogenic variant.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024